Trialssemaglutidetype 2 diabetesreal-world evidencelmc diabetes

Canadian registry study tracks three-year semaglutide HbA1c outcomes

LMC Diabetes & Endocrinology's retrospective analysis compares semaglutide initiators with those starting sulfonylureas, DPP-4 inhibitors or SGLT2 inhibitors.

By Priya Raman · Science Reporter

Oct 13 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07424430, listed as completed, uses the LMC Diabetes Registry to measure change in HbA1c from baseline to three years in adults with type 2 diabetes who started semaglutide.
02Real-world cardio-kidney-metabolic data on longitudinal semaglutide use speaks to durability questions clinicians face beyond the registration trials.
03The study is retrospective and sponsor-run, with obesity patients without diabetes assessed separately; results are not yet published.

From the source

Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
NCT07424430 · N/A · COMPLETED · Sponsor: LMC Diabetes & Endocrinology Ltd. · Conditions: Diabetes (DM), Type 2 Diabetes, Obesity (Disorder).

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07424430